The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Current Issue | New England Journal of Medicine
Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).
Recently Published - The New England Journal of Medicine
Nov 29, 2025 · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).
About NEJM - The New England Journal of Medicine
The New England Journal of Medicine (NEJM) is recognized as the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed ...
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
May 11, 2025 · Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without …
Extended Reduced-Dose Apixaban for Cancer-Associated Venous ...
Mar 29, 2025 · In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent …
Perioperative Durvalumab in Gastric and Gastroesophageal Junction ...
Jun 1, 2025 · Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates …
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Jun 1, 2025 · Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured …
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 ...
Mar 29, 2025 · The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An …
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal …
May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic …